Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.
Cholecystokinin (CCK) has been shown to promote pancreatic growth and azaserine-induced pancreatic carcinogenesis in rats. The present study was carried out to determine effects of CCK on pancreatic growth and carcinogenesis in the N-nitrosobis(2-oxopropyl)amine (BOP) hamster model. One hundred male Syrian golden hamsters were injected s.c. once weekly with 20 mg BOP/kg body wt at 6, 7 and 8 weeks of age, and divided into four groups of 25 animals each, which received one of the following treatments (once daily, 3 days/week for 16 weeks): gelatin; CR-1409, a potent CCK-receptor antagonist; CCK-8, 2.5 micrograms/kg body wt; or CCK-8 in combination with CR-1409 (30 min before CCK treatment). The animals were killed after 19 weeks. The growth of the pancreas but not the incidence of pancreatic (pre)neoplastic lesions was enhanced by CCK-8. CR-1409 did not influence the effect of CCK on pancreatic growth.
Meijers
M
M
Department of Biological Toxicology, TNO-CIVO Toxicology and Nutrition Institute, Zeist, The Netherlands.
van Garderen-Hoetmer
A
A
Lamers
C B
CB
Rovati
L C
LC
Jansen
J B
JB
Woutersen
R A
RA
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens; D002766:Cholecystokinin / Q000009:adverse effects* / Q000493:pharmacokinetics; D003043:Cocarcinogenesis; D006224:Cricetinae; D008297:Male; D009602:Nitrosamines; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000139:chemically induced*; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology
D002273:Carcinogens; D009602:Nitrosamines; C013622:nitrosobis(2-oxopropyl)amine; D002766:Cholecystokinin; D011377:Proglumide; C048181:lorglumide